RONA Therapeutics - About the company
RONA Therapeutics is a series A company based in Shanghai (China), founded in 2021. It operates as a Developer of oligonucleotide therapeutics to treat multiple diseases. RONA Therapeutics has raised $68M in funding from LongRiver Investments. The company has 565 active competitors, including 208 funded and 133 that have exited. Its top competitors include companies like Alnylam, Spark Therapeutics and Moderna.
Company Details
Developer of oligonucleotide therapeutics to treat multiple diseases. The company focuses on the discovery and development of modular and programmable RNA medicines targeting disease areas across metabolic diseases, neurological diseases, and ophthalmology diseases by using proprietary delivery systems.
Key Metrics
Founded Year
2021
Location
Shanghai, China
Stage
Series A
Total Funding
$68M in 2 rounds
Latest Funding Round
Investors
Ranked
84th among 565 active competitors
Employee Count
20 as on Aug 31, 2026
Sign up to download RONA Therapeutics' company profile
RONA Therapeutics's funding and investors
RONA Therapeutics has raised a total funding of $68M over 2 rounds. Its first funding round was on Apr 07, 2022. Its latest funding round was a Series A round on Jul 19, 2024 for $*****. 4 investors participated in its latest round. RONA Therapeutics has 9 institutional investors.
Here is the list of recent funding rounds of RONA Therapeutics:
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Jul 19, 2024 | 4873214 | Series A | 7171011 | 1643166 | 2750452 | 8770663 |
Apr 07, 2022 | 6520159 | Series A | 1491878 | 6168703 | 6375301 |
Access funding benchmarks and valuations. Sign up today!View details of RONA Therapeutics's funding rounds and investors
RONA Therapeutics' founders and board of directors
Founder? Claim ProfileRONA Therapeutics' employee count trend
RONA Therapeutics has 20 employees as of Aug 26. Here is RONA Therapeutics's employee count trend over the years:
Uncover RONA Therapeutics' growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
RONA Therapeutics's Competitors and alternates
Top competitors of RONA Therapeutics include Alnylam, Spark Therapeutics and Moderna. Here is the list of Top 10 competitors of RONA Therapeutics, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | Alnylam 2002, Cambridge (United States), Public | Developer of RNA interference-based therapeutics for multiple disorders | $17M | 79/100 | |
2nd | Spark Therapeutics 2013, Philadelphia (United States), Acquired | Developer of gene therapy for rare diseases | $82.8M | 73/100 | |
3rd |  Moderna 2010, Cambridge (United States), Public | Developer of mRNA-based therapeutics for a wide range of diseases | $2.78B | 71/100 | |
4th |  Forge Biologics 2020, Columbus (United States), Acquired | Developer of gene therapeutic solutions for treating multiple diseases | $330M | 70/100 | |
5th |  Strand Therapeutics 2017, Cambridge (United States), Series B | Provider of platform to deliver mRNA therapeutics for multi functional treatments | $256M | 70/100 | |
6th | _1560516450043.png?devicePixelRatio=2&height=30&width=30){kind=logo} Passage Bio 2017, Philadelphia (United States), Public | Developer of gene therapies for CNS rare diseases | $226M | 69/100 | |
7th | Ultragenyx 2010, Novato (United States), Acquired | Developer of therapeutics for the treatment of rare and ultra-rare metabolic diseases | $135M | 69/100 | |
8th |  Generation Bio 2016, Cambridge (United States), Acquired | Developer of gene therapies for rare liver and eye diseases | $236M | 69/100 | |
9th | ElevateBio 2018, Cambridge (United States), Series D | Provider of transnational research for portfolio of cell and gene therapy | $1.25B | 68/100 | |
10th | Krystal Biotech 2015, Pittsburgh (United States), Public | Developer of genetic medicines to treat rare diseases | $11.3M | 67/100 | |
84th |  RONA Therapeutics 2021, Shanghai (China), Series A | Developer of oligonucleotide therapeutics to treat multiple diseases | $68M | 55/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on RONA Therapeutics's competitors? Click here to see the top ones
RONA Therapeutics's Investments and acquisitions
RONA Therapeutics has made no investments or acquisitions yet.
News related to RONA Therapeutics
Filter this listMedia has covered RONA Therapeutics for a total of 4 events in the last 1 year, 3 of them have been about company updates.
•
•
•
•
•
•
•
•
•
•
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about RONA Therapeutics
Explore our recently published companies
- Dragon Queen Design&Print - Hamilton based, Unfunded company
- Linha Uni - Sao Paulo based, 2020 founded, Seed company
- QualiBlaze Consulting - Johannesburg based, Unfunded company
- Bengawan Solo - Singapore based, 1997 founded, Unfunded company
- Love Your Pet Raw Foods - Park City based, 1991 founded, Unfunded company
- Fine Test Lite - Cairo based, 2021 founded, Unfunded company
